Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)-MedSci.cn

Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)

Tahara, M; Brose, MS; Wirth, L; Suzuki, T; Fujino, K; Batty, N; Dutcus, C; Gianoukakis, A

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务